All In Biotech

Drug Trial Radar · NCT04034134

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Severe Alopecia Areata.

Last checked: Nov 19, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Nov 18, 2019

Primary completion

Nov 26, 2021

Study completion Nov 26, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.

Conditions

  • Alopecia Areata

Interventions

  • Jaktinib Hydrochloride TabletsDrug

    50 mg twice-daily (BID)

  • Jaktinib Hydrochloride TabletsDrug

    150 mg quaque die (QD)

  • Jaktinib Hydrochloride TabletsDrug

    200 mg quaque die (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effective rateTime frame: From randomization of the first subject until the last subject complete 6 months treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing Chinese Traditional Medicine Hospital

    Chongqing, Chongqing Municipality, China

  • The second xaingya hospital of central south university

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.